DJIA 17,050.75 138.46 0.82%
NASDAQ 4,810.79 19.64 0.41%
S&P 500 2,013.43 17.60 0.88%
market minute promo

Regeneron Pharmaceuticals (NASDAQ: REGN)

491.21 5.45 (1.12%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

REGN $491.21 1.12%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $482.78
Previous Close $485.76
Daily Range $468.54 - $496.68
52-Week Range $320.06 - $605.93
Market Cap $50.9B
P/E Ratio 122.67
Dividend (Yield) $0.00 (0.0%)
Volume 839,216
Average Daily Volume 975,872
Current FY EPS $9.39




Drug Makers

Regeneron Pharmaceuticals (REGN) Description

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions. Website:

News & Commentary

Cholesterol Busters Will Be Cheaper but Remain Top Sellers

Express Scripts has negotiated lower prices for next-generation cholesterol drugs, but spending on them will remain next year.

Stock Market News for October 08, 2015

The Zacks Analyst Blog Highlights: Amgen, Regeneron, Acorda, Amicus and AbbVie

Express Scripts Includes Praluent and Repatha in Formulary

Biotech Stock Roundup: PBM Lists Both Amgen & Regeneron PCSK9 Inhibitors, FOLD Plunges on NDA Delay

Commit To Buy Regeneron Pharmaceuticals At $320, Earn 6.6% Using Options

Nasdaq 100 Movers: ADBE, WYNN

Strong On High Relative Volume: Regeneron Pharmaceuticals (REGN)

Illumina (ILMN) Shares Tumble on Weak Outlook for Sales

Would an Ebola Vaccine Move Regeneron Pharmaceuticals' Bottom Line?

Regeneron Pharmaceuticals has won a BARDA agreement to develop a potential vaccine for the Ebola virus. How big of a deal is it for Regeneron investors today?

See More REGN News...

REGN's Top Competitors

REGN $491.21 (1.12%)
Current stock: REGN
AMGN $149.90 (1.25%)
Current stock: AMGN
GILD $100.81 (0.54%)
Current stock: GILD
BIIB $279.88 (0.23%)
Current stock: BIIB